Cardiovascular Proteomics: A Post-hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist Vs GnRH Agonist Among Men with Advanced Prostate Cancer.

Karin Lifshitz,Yaara Ber,Chen Shenhar,Jan Nillson,Avivit Peer,Eli Rosenbaum,Jack Baniel,Daniel Kedar,Osnat Itzhaki Ben Zadok,David Margel

Cardiovascular Proteomics: A Post-hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist Vs GnRH Agonist Among Men with Advanced Prostate Cancer.

2021

Karin Lifshitz
Yaara Ber
Chen Shenhar
Jan Nillson
Avivit Peer
Eli Rosenbaum
Jack Baniel
Daniel Kedar
Osnat Itzhaki Ben Zadok
David Margel

Purpose:Recent studies demonstrated reduced cardiovascular (CV) risk with gonadotropin-releasing hormone (GnRH) antagonist, yet the underlying mechanism remains undetermined. The objective of this ...

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations